Sonoma Pharmaceuticals Overview
- Founded
-
1999

- Status
-
Public
- Employees
-
177

- Stock Symbol
-
SNOA

- Investments
-
1
- Share Price
-
$3.01
- (As of Wednesday Closing)
Sonoma Pharmaceuticals General Information
Description
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing and commercializing differentiated therapies to patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes and others. The company derives revenue from the sale of products in the United States, Latin America, Europe and other countries.
Contact Information
- 1129 North McDowell Boulevard
- Petaluma, CA 94954
- United States
Sonoma Pharmaceuticals Stock Performance
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$3.01 | $3.10 | $2.55 - $13.36 | $9.6M | 3.1M | 79.1K | -$1.71 |
Sonoma Pharmaceuticals Financials Summary
In Thousands, USD |
TTM 30-Jun-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
---|---|---|---|---|
EV | 1,850 | 5,103 | 11,875 | 6,081 |
Revenue | 12,927 | 12,628 | 18,629 | 17,928 |
EBITDA | (5,064) | (5,222) | (3,679) | (3,266) |
Net Income | (4,875) | (5,086) | (3,950) | (3,308) |
Total Assets | 17,158 | 18,845 | 14,987 | 14,561 |
Total Debt | 952 | 1,367 | 2,675 | 850 |
Sonoma Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Sonoma Pharmaceuticals Comparisons
Industry
Sonoma Pharmaceuticals Competitors (6)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Orthofix International | Formerly PE-Backed | Lewisville, TX | 0000 | 00000000 | ||
0000 000 | Formerly VC-backed | Malvern, PA | 000 | 00000 | 00000000 | 00000 |
000000 | Corporation | Marietta, GA | 000 | 00000 | 000000000 | 00000 |
00000 | Formerly VC-backed | Columbia, MD | 000 | 000.00 | 000000&0 | 000.00 |
000000 000000 | Corporation | Warsaw, IN | 00000 | 00.000 | 000000 - 000 | 00.000 |
Sonoma Pharmaceuticals Patents
Sonoma Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-9918477-B2 | Stabilized hypochlorous acid solution and use thereof | Active | 22-May-2013 | 000000000 | |
US-20160120183-A1 | Stabilized hypochlorous acid solution and use thereof | Granted | 22-May-2013 | 000000000 | |
US-10412969-B2 | Stabilized hypochlorous acid solution and use thereof | Active | 22-May-2013 | 000000000 | |
US-20180206502-A1 | Stabilized hypochlorous acid solution and use thereof | Granted | 22-May-2013 | 000000000 | |
JP-2016521684-A | Stabilized hypochlorous acid solution and use thereof | Granted | 22-May-2013 | A01N59/00 |
Sonoma Pharmaceuticals Executive Team (15)
Sonoma Pharmaceuticals Board Members (12)
Name | Representing | Role | Since |
---|---|---|---|
Amy Trombly | Sonoma Pharmaceuticals | Chief Executive Officer & Board Member | 000 0000 |
Jay Birnbaum Ph.D | Self | Board Member | 000 0000 |
Jerry McLaughlin | Self | Board Member | 000 0000 |
Philippe Weigerstorfer | Sonoma Pharmaceuticals | Board Member | 000 0000 |
Sonoma Pharmaceuticals Signals
Sonoma Pharmaceuticals Investments (1)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
0.0. 00000000 | 01-Jan-2015 | 000000000 | Buildings and Property |